SEC Form 4 · accession 0001615774-18-000388
Ensysce Biosciences, Inc. · ENSC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jan 15, 2018
Accepted (ET)
Jan 17, 2018 · 5:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001716947
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 15, 2018 | J | 40,645 | $0.00 | D | 266,900 | D | |
| Common StockF2,F3 | Jan 15, 2018 | J | 132,158 | $0.00 | D | 867,842 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1As contemplated by the securities subscription agreement between such reporting person and the Company, 40,645 shares held by Mr. Weil were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering.
- F2As contemplated by the securities subscription agreement between such reporting person and the Company, 132,158 shares held by Hydra LAC, LLC, an affiliate of a sponsor of the Company (the "Sponsor Affiliate"), were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering.
- F3Represents shares of common stock held by the Sponsor Affiliate. The shares held by the Sponsor Affiliate are beneficially owned by A. Lorne Weil, who has sole voting and dispositive power over the shares held by the Sponsor Affiliate. Mr. Weil owns all of the membership interests in the Sponsor Affiliate. Mr. Weil disclaims beneficial ownership over any securities owned by the Sponsor Affiliate in which he does not have any pecuniary interest.